研究等業績 - その他 - 三浦 昌朋
-
Fujita K.
Cancer Chemotherapy and Pharmacology ( Cancer Chemotherapy and Pharmacology ) 95 ( 1 ) 2025年12月
-
Yokota H.
Cancer Chemotherapy and Pharmacology ( Cancer Chemotherapy and Pharmacology ) 95 ( 1 ) 2025年12月
-
Terasawa A.
World Journal of Experimental Medicine ( World Journal of Experimental Medicine ) 15 ( 2 ) 2025年06月
-
LM1010高速液体クロマトグラフィ法と化学発光免疫測定法によるバンコマイシン血中濃度測定値の比較
赤嶺 由美子, 松下 美由紀, 森川 悟, 三浦 昌朋
医療薬学 ( 一般社団法人日本医療薬学会 ) 51 ( 4 ) 187 - 195 2025年04月
<p>Many immunoassay methods have been developed for quantifying vancomycin levels in biological fluids. Recently, the LM1010, a high-performance liquid chromatography-based medical diagnostic device was approved. This study compared the results obtained with LM1010 with those obtained using ARCHITECT plus chemiluminescent immunoassay (CLIA) to measure vancomycin levels in patient serum samples. The retention times measured with LM1010 for vancomycin and its major and minor crystalline degradation products (CDP-1) were 2.50, 2.38, and 1.91 min, respectively, and the separation was satisfactory. When five CLIA calibrator samples (5.0 – 100 μg/mL) were analyzed using LM1010, the concentrations were lower than expected, with an average of −12.96％ (range: −7.07％ to −17.53％). In addition, in a Japanese external quality control survey examination, LM1010 demonstrated high accuracy (0.33％ to −6.68％). A strong correlation was observed between the results obtained using LM1010 (calculated by peak height) and CLIA (<i>r</i> = 0.9682). The slope of the Deming regression comparing LM1010 to CLIA was 0.831, and a Bland–Altman plot for LM1010 relative to CLIA showed a mean negative bias (±1.96 standard deviation) of −2.356 (−6.108 – 1.396) μg/mL. Thus, the results obtained with CLIA were higher than those obtained with LM1010. If the calibrators for CLIA are adjusted by considering cross-reactivities with CDP-1 or other metabolites, the vancomycin concentrations in patient samples determined using CLIA may be higher than those determined using LM1010. Overall, vancomycin concentrations should be analyzed using an assay with higher accuracy, such as LM1010.</p>
-
Abumiya M.
International Journal of Hematology ( International Journal of Hematology ) 2025年
-
高速液体クロマトグラフィ分析装置LM1010を用いたフェニトインとカルバマゼピンの同時血中濃度定量と化学発光免疫測定法との比較
赤嶺 由美子, 松下 美由紀, 森川 悟, 三浦 昌朋
医療薬学 ( 一般社団法人日本医療薬学会 ) 50 ( 9 ) 465 - 472 2024年09月
<p>LM1010 high-performance liquid chromatography system was recently approved as a medical diagnostic device. Phenytoin and carbamazepine—the antiepileptic drugs—can be detected simultaneously using LM1010; however, the accuracy of quantification of these two drugs in serum using this system has not been established. Herein, we compared the performance of LM1010 in measuring phenytoin and carbamazepine with that of an established chemiluminescent immunoassay (CLIA）using the ARCHITECT system. When CLIA calibrator samples were examined using both methods, the accuracy of LM1010 was within 3.20％ for phenytoin and 6.50％ for carbamazepine. Moreover, the two methods were applied to serum samples from subjects taking phenytoin (n = 95）or carbamazepine (n = 69). The slopes of Deming regression curves comparing LM1010 to CLIA for phenytoin and carbamazepine were 0.984 and 0.943, respectively. Further, Bland–Altman analyses showed an average positive bias (±1.96 × SD）of 0.180 (−1.998 – 2.359）μg/mL for phenytoin and 0.001 (−1.171 – 1.174）μg/mL for carbamazepine using LM1010 relative to CLIA. There were strong correlations between results from LM1010 and CLIA for serum phenytoin and carbamazepine (Spearman’s <i>r</i> = 0.9836 and 0.9754, respectively). The difference in the measurements of serum concentrations of carbamazepine was partially yet significantly negatively correlated with serum hemoglobin (slope = −0.1094). Thus, we successfully applied LM1010 to the simultaneous determination of serum concentrations of phenytoin and carbamazepine and concluded that this system can be used for routine therapeutic drug monitoring.</p>
-
Safety and efficacy of asciminib in a patient with chronic myeloid leukemia on hemodialysis
Naka R.
International Journal of Hematology ( International Journal of Hematology ) 121 ( 2 ) 272 - 275 2024年
-
Numakura K.
Cancer Biology and Therapy ( Cancer Biology and Therapy ) 25 ( 1 ) 2024年
-
Fujita K.
Investigational New Drugs ( Investigational New Drugs ) 42 ( 3 ) 252 - 260 2024年
-
Kobayashi T.
Cancer Chemotherapy and Pharmacology ( Cancer Chemotherapy and Pharmacology ) 94 ( 2 ) 285 - 296 2024年
-
Ureshino H.
International Journal of Hematology ( International Journal of Hematology ) 120 ( 4 ) 492 - 500 2024年
-
Kobayashi Takahiro, Honami Sato, Miura Masatomo, Fukushi Yayoi, Kuroki Wataru, Ito Fumiko, Teshima Kazuaki, Watanabe Atsushi, Fujishima Naohito, Kobayashi Isuzu, Kameoka Yoshihiro, Takahashi Naoto
Cancer Chemotherapy and Pharmacology ( Springer Nature ) 2024年
-
Kobayashi T.
Xenobiotica ( Xenobiotica ) 55 ( 1 ) 37 - 42 2024年
-
Fujita K.
Drugs - Real World Outcomes ( Drugs - Real World Outcomes ) 12 ( 1 ) 153 - 160 2024年
-
Machine learning prediction of drug dynamics in dasatinib
Mutsu R.
Proceedings - 2024 12th International Symposium on Computing and Networking Workshops, CANDARW 2024 ( Proceedings - 2024 12th International Symposium on Computing and Networking Workshops, CANDARW 2024 ) 400 - 402 2024年
-
ミコフェノール酸AUCの算出のためのBayesian法の確立とその精度
三浦 昌朋, 笠井 英史, 加賀谷 英彰, 新岡 丈典, 齋藤 満, 佐藤 滋
移植 ( 一般社団法人 日本移植学会 ) 59 ( Supplement ) s292_2 - s292_2 2024年
<p>【目的】ミコフェノール酸(MPA)は、AUC0-12として30-60 mg.hr/Lを指標にTDMの実施が推奨されている。しかしAUC算出には複数採血が必要でありTDMが十分に実施されていない。今回我々は腎移植患者を対象にBayesianに基づいたAUC推定法を確立し、その精度を確認した。【方法】腎移植術後21日目から699日目のタクロリムスとセルセプト併用日本人腎移植患者のべ752名のMPAトラフ濃度から投与後12時間までの血中濃度計5,809点から、1-compartment modelを用いてBayesian法を確立した。さらにBayesian法によるAUC推定値の精度を確認するために、Bayesian法確立患者群と異なる患者45名からWInNonlinによる実測AUC値を算出し、Bayesian推定AUC値と比較した。【結果】Bayesian推定AUC値と実測AUC間で最も高い相関を示したのは、1点採血ではトラフ値(C0, r=0.848)であり、次いで投与後9時間(C9, r=0.765)であった。2点採血の場合、C0-C2でr=0.905、3点採血C0-C2-C3のrは0.931であった。また腸肝循環の情報が含まれるC9を考慮した場合、C0-C2-C9のrは0.941と高い相関を示した。このBayesian式を用いて、式確立患者群と異なる群のAUCを予測した結果、C2が最もAUCを予測(r=0.645)し、2点の場合、C0-C3でr=0.723、3点の場合C0-C2-C3でr=0.816、C2-C3-C9でr=0.904であった。【考察】今回開発したBayesian式は高い精度でAUCを予測できると考える。今後本BayesianによるMPAのAUC解析ソフトを配布予定である。</p>
-
Fukuda N.
Journal of chromatographic science ( Journal of chromatographic science ) 62 ( 1 ) 58 - 64 2023年12月
-
Yokota H.
Cancer Chemotherapy and Pharmacology ( Cancer Chemotherapy and Pharmacology ) 92 ( 4 ) 315 - 324 2023年10月
-
Fukuhara T.
Biomedicines ( Biomedicines ) 11 ( 9 ) 2023年09月
-
Akamine Y.
Yakugaku Zasshi ( Yakugaku Zasshi ) 143 ( 4 ) 377 - 383 2023年
<p>Plasma concentrations of mycophenolic acid (MPA), an immunosuppressive agent, have been measured in clinical settings using immunoassay methods or HPLC. However, immunoassay methods show cross-reactivity with metabolites of MPA glucuronide. Recently, the LM1010 high-performance liquid chromatography instrument was approved as a new general medical device. In this study, we compared the results of MPA plasma concentrations analyzed using the LM1010 method and the previously described HPLC method. Plasma samples obtained from 100 renal transplant patients (32 women and 68 men) were evaluated using both HPLC instruments. Deming regression analyses showed a very high correlation between the two instruments, with a slope of 0.9892 and an intercept of 0.0235 µg/mL (<i>r</i><sup>2</sup>=0.982). Bland–Altman analysis showed an average of −0.0012 µg/mL between the LM1010 method and the previously described HPLC method. For the LM1010 method, the total run time for MPA analysis was 7 min, and the analytical time was short; however, the extraction recovery when using a spin column was extremely low for frozen plasma samples stored at −20°C for 1 month, and the volume required for the assay (150 µL) could not be collected. Thus, for the LM1010 method, analysis using fresh plasma samples was optimal. Overall, our findings showed that the LM1010 method was a rapid, accurate HPLC assay for MPA analysis and could be used in clinical practice for routine monitoring of MPA in fresh plasma samples.</p>